The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

The Laser Therapy Devices market is expected to reach approximately USD 3.6 billion in 2025 and expand to around USD 8.3 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.8% over ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the ...

A trial of an interactive game that trains people to alter their brain waves has shown promise as a treatment for nerve pain ...

The following is a summary of “Neuropathic Pain in Nursing Homes,” published in the May 2025 issue of European Journal of ...

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

Pregabalin has demonstrated efficacy in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for adult patients with ...

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain ... 25% of the AP-325 treated patients showed a pain reduction of at least ...

a The three most commonly used maintenance doses are depicted. b Patients taking 25-50 mg once daily should take one supplemental pregabalin dose of 50 or 75 mg after hemodialysis. c Patients ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Chronic pain conditions, long-lasting medical conditions characterized by persistent pain in specific areas of the body, are ...